Search Result

Results for "

thrombin inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Protease Activated Receptor (PAR) (24) Thrombin (130) 5-HT Receptor (4) Amino Acid Derivatives (2) Amyloid-β (2) Antibiotic (1) AP-1 (1) Apoptosis (10) Autophagy (1) Bacterial (5) Biochemical Assay Reagents (3) Caspase (2) Cathepsin (2) Complement System (1) COX (3) Dengue Virus (2) Deubiquitinase (1) Dihydroorotate Dehydrogenase (2) Drug Isomer (1) Drug Metabolite (3) Elastase (3) Endogenous Metabolite (1) Environmental Pollutants (1) ERK (2) Exosomes (1) Factor VIIa (2) Factor VIII (1) Factor Xa (34) Factor XI (1) FAP (1) Ferroptosis (2) Fluorescent Dye (4) FOXO (1) Fungal (1) Glutathione Peroxidase (2) Heme Oxygenase (HO) (2) Influenza Virus (2) Insecticide (2) Integrin (3) Interleukin Related (2) Isotope-Labeled Compounds (10) JAK (1) JNK (3) Kallikrein (4) Keap1-Nrf2 (2) NF-κB (4) NOD-like Receptor (NLR) (1) p38 MAPK (1) PAI-1 (4) PANoptosis (1) Phosphatase (1) Phosphodiesterase (PDE) (4) PKC (6) Platelet-activating Factor Receptor (PAFR) (1) Potassium Channel (1) Proteasome (3) Proton Pump (2) Reference Standards (21) RSV (2) SARS-CoV (2) Ser/Thr Protease (21) Sirtuin (1) Small Interfering RNA (siRNA) (5) Src (1) Syk (1) Tissue Factor Pathway Inhibitor (TFPI) (2) Toll-like Receptor (TLR) (2) TRP Channel (2) Virus Protease (1)
By Research Areas:	Cancer (27) Cardiovascular Disease (160) Endocrinology (3) Infection (15) Inflammation/Immunology (38) Metabolic Disease (9) Neurological Disease (8)
Oligonucleotides:	Aptamers (3) siRNA drugs (5) siRNAs (5)

218

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: Thrombin Protease Activated Receptor (PAR)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12821

AEBSF hydrochloride 15+ Cited Publications	Thrombin Influenza Virus Ser/Thr Protease	Others
AEBSF hydrochloride is an irreversible inhibitor of serine proteases, such as chymotrypsin, kallikrein, plasmin, thrombin, and trypsin.

HY-P1929

Bivalirudin Maximum Cited Publications 9 Publications Verification	Thrombin Interleukin Related RSV	Infection Cardiovascular Disease Inflammation/Immunology
Bivalirudin, a hirudin analog and anticoagulant, is a direct *thrombin* inhibitor. Bivalirudin inhibits thrombin-mediated fibrinogen cleavage, coagulation factor activation, and platelet activation by reversibly binding to thrombin. In addition, Bivalirudin also has certain effects of anti-virus, anti-inflammation, and vascular endothelial barrier function protection. Bivalirudin can be used for the research of thrombotic diseases and others .

HY-B0375

Argatroban 5 Publications Verification MD-805; MCI-9038	Thrombin	Cardiovascular Disease Cancer
Argatroban (MD-805) is a direct, selective thrombin inhibitor.

HY-10119

Vorapaxar 10+ Cited Publications SCH 530348	Protease Activated Receptor (PAR)	Cardiovascular Disease
Vorapaxar (SCH 530348), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor protease-activated receptor (PAR-1) antagonist (K_i=8.1 nM). Vorapaxar (SCH 530348) inhibits thrombin receptor-activating peptide (TRAP)-induced platelet aggregation in a dose-dependent manner .

HY-10163

Dabigatran 5+ Cited Publications BIBR 953; BIBR 953ZW	Thrombin	Cardiovascular Disease Cancer
Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct *thrombin* inhibitor (K_i=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC₅₀=10 nM) .

HY-132587

Fitusiran ALN-AT3SC; SAR439774	Factor Xa Small Interfering RNA (siRNA) Thrombin	Cardiovascular Disease
Fitusiran (ALN-AT3SC) is a siRNA strategy. Fitusiran delivers siRNA targeting the SERPINC1 gene in hepatocytes to inhibit antithrombin synthesis. Fitusiran enhances thrombin activity and increases *Thrombin* generation, thereby restoring hemostatic function. Fitusiran can be used in hemophilia-related research .

HY-P0074

GPRP 3 Publications Verification Gly-Pro-Arg-Pro; Pefa 6003	Thrombin	Cardiovascular Disease
GPRP (Gly-Pro-Arg-Pro; Pefa 6003) is a fibrin polymerization inhibitor that inhibits the interaction between fibrinogen and the platelet membrane glycoprotein Ⅱb/IIIa complex (glycoprotein IIb/IIIa receptor) . GPRP increases the level of free thrombin in activated platelet-rich plasma by reducing the adsorption of *thrombin* onto fibrin. GPRP inhibits platelet aggregation and prolongs the thrombin-initiated clotting time in plasma. GPRP is applicable for research related to thrombosis and thrombotic diseases .

HY-10119A

Vorapaxar sulfate 10+ Cited Publications SCH 530348 sulfate	Protease Activated Receptor (PAR)	Cardiovascular Disease
Vorapaxar sulfate (SCH 530348 sulfate), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor protease-activated receptor (PAR-1) antagonist (K_i=8.1 nM). Vorapaxar sulfate inhibits thrombin receptor-activating peptide (TRAP)-induced platelet aggregation in a dose-dependent manner .

HY-125913

Benzamidine 3 Publications Verification	Ser/Thr Protease	Inflammation/Immunology
Benzamidine is a competitive protease inhibitor that blocks the hydrolytic cleavage of glucagon by plasmin, trypsin and thrombin. Benzamidine effectively inhibits the degradation of glucagon by relevant proteases during the collection, storage and analysis of human plasma and blood samples. During in vivo metabolism, Benzamidine undergoes N-hydroxylation and produces multiple metabolites, exhibiting characteristics of delayed excretion or biphasic elimination. Benzamidine only induces slight single-strand DNA breaks at high concentrations and shows no significant genotoxic potential overall. Benzamidine may interfere with the detection of some glucagon antisera, but does not affect key antigen-antibody affinity at specific concentrations. Benzamidine can be used as a stabilizer in glucagon radioimmunoassays to ensure the accuracy and recovery rate of detection results .

HY-10787

Ximelagatran 1 Publications Verification H 376/95	Thrombin	Cardiovascular Disease
Ximelagatran (H 376/95) is an orally active *thrombin* inhibitor that selectively and competitively inhibits both free and clot-bound *thrombin*. Ximelagatran is an anticoagulant agent with a rapid onset of anticoagulant effect, predictable, dose-dependent pharmcokinetics and pharmacodynamics .

HY-B0375A

Argatroban monohydrate 5 Publications Verification MD-805 monohydrate; MCI-9038 monohydrate	Thrombin	Cardiovascular Disease Infection Cancer
Argatroban (monohydrate) (MD-805 (monohydrate)) is a direct, selective thrombin inhibitor.

HY-15664

Bivalirudin TFA Maximum Cited Publications 9 Publications Verification	Thrombin Interleukin Related RSV	Infection Cardiovascular Disease Inflammation/Immunology
Bivalirudin TFA, a hirudin analog and anticoagulant, is a direct *thrombin* inhibitor. Bivalirudin TFA inhibits thrombin-mediated fibrinogen cleavage, coagulation factor activation, and platelet activation by reversibly binding to thrombin. In addition, Bivalirudin TFA also has certain effects of anti-virus, anti-inflammation, and vascular endothelial barrier function protection. Bivalirudin TFA can be used for the research of thrombotic diseases and others .

HY-17378

Dabigatran ethyl ester 1 Publications Verification	Thrombin	Cardiovascular Disease
Dabigatran ethyl ester is an inhibitor of ribosyldihydronicotinamide dehydrogenase (NQO2) and thrombin. Dabigatran ethyl ester inhibits NADH-dependent metabolism of mitomycin C mediated by purified recombinant human NQO2 .

HY-129056

Melagatran	Thrombin NF-κB AP-1	Cardiovascular Disease Neurological Disease
Melagatran is a reversible, selective, orally active direct inhibitor of *thrombin* with a K_i of 2 nM. Melagatran binds directly to the active site of thrombin, inhibiting thrombin-mediated conversion of fibrinogen to fibrin. Melagatran reduces the DNA binding activity of NF-κB and AP-1. Melagatran reduces fibrin deposition in organs, alleviates ischemic brain damage, and reduces the size of advanced atherosclerotic lesions. Melagatran can be used in the study of cardiovascular disease (coronary thrombosis, atherosclerosis) and ischemic brain damage .

HY-132587A

Fitusiran sodium ALN-AT3SC sodium; SAR439774 sodium	Factor Xa Small Interfering RNA (siRNA) Thrombin	Cardiovascular Disease
Fitusiran (ALN-AT3SC) sodium is a siRNA strategy. Fitusiran delivers siRNA targeting the SERPINC1 gene in hepatocytes to inhibit antithrombin synthesis. Fitusiran sodium enhances thrombin activity and increases *Thrombin* generation, thereby restoring hemostatic function. Fitusiran sodium can be used in hemophilia-related research .

HY-10217

Thrombin Inhibitor 2	Thrombin	Cardiovascular Disease
Thrombin Inhibitor 2 is a small molecule direct *thrombin* inhibitor, extracted from US8541580B2. Thrombin Inhibitor 2 has antithrombotic activity .

HY-10163S

Dabigatran-d4 BIBR 953-d₄; BIBR 953ZW-d₄	Isotope-Labeled Compounds Thrombin	Cardiovascular Disease
Dabigatran-d₄ is deuterium labeled Dabigatran. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC₅₀=10 nM) .

HY-N10762

15,16-Dihydrotanshindiol C	Thrombin	Cardiovascular Disease
15,16-Dihydrotanshindiol C, a diterpenoid, is a potent *thrombin* inhibitor .

HY-10163S1

Dabigatran-d3 BIBR 953-d₃; BIBR 953ZW-d₃	Thrombin	Cardiovascular Disease
Dabigatran-d₃ is the deuterium labeled Dabigatran. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC₅₀=10 nM) .

HY-10163R

Dabigatran (Standard) BIBR 953 (Standard); BIBR 953ZW (Standard)	Reference Standards Thrombin	Cardiovascular Disease Cancer
Dabigatran (Standard) is the analytical standard of Dabigatran. This product is intended for research and analytical applications. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM) .

HY-P4325

Hirudin (55-65) sulfated	Thrombin	Others
Hirudin (55-65) (sulfated) is a fragment of Hirudin with anticoagulant effects. Hirudin is a thrombin inhibitor with blood anticoagulant property.

HY-151983

Thrombin inhibitor 6	Thrombin	Cardiovascular Disease
Thrombin inhibitor 6 is a potent thrombin inhibitor (IC₅₀: 1 nM). Thrombin inhibitor 6 has the function as an anticoagulant .

HY-148037

Thrombin inhibitor 5	Proteasome	Cardiovascular Disease
Thrombin inhibitor 5 (compound 385) is a *thrombin* inhibitor, with IC₅₀s ranging from 0.1 μM to 1 μM. Thrombin inhibitor 5 can be used for research of venous thromboembolism .

HY-152150

Thrombin inhibitor 7	Ser/Thr Protease	Metabolic Disease
Thrombin inhibitor 7 is a potent FXIIa inhibitor with IC₅₀ values of 28 nM, >132 µM for FXIIa and FXIa, respectively. Thrombin inhibitor 7 shows low cytotoxicity .

HY-10273

Atecegatran metoxil AZD0837; Atecegatran fexenetil	Thrombin	Cardiovascular Disease
Atecegatran metoxil is a oral anticoagulant, which inhibits thrombin factor II and is used in thromboembolic disorders. In vivo, Atecegatran metoxil is converted to AR-H067637, a selective and reversible direct *thrombin* inhibitor.

HY-174285

NAPAP	Thrombin	Cardiovascular Disease
NAPAP is a selective direct *thrombin* inhibitor. NAPAP rapidly binds to thrombin and inhibits its activity, and reduces LPS (HY-D1056)-induced brain inflammation and coagulation factor expression in vivo. NAPAP can be used in studies related to coagulation and neuroinflammation .

HY-P991065

Ichorcumab JNJ-375; JNJ-64179375; JNJ-9375	Thrombin	Cardiovascular Disease
Ichorcumab (JNJ-375) is a fully human IgG4 antibody that targets *Thrombin. Ichorcumab binds to exosite 1 on thrombin* and inhibits substrate binding but not catalytic activity. The isotype control for Ichorcumab can refer to Human IgG4 kappa, Isotype Control (HY-P99003) .

HY-10163AS

Dabigatran-d4 hydrochloride BIBR-953-d4 hydrochloride	Thrombin	Cardiovascular Disease
Dabigatran-d₄ (hydrochloride) is deuterium labeled Dabigatran, which is a reversible and selective, direct thrombin inhibitor (DTI) with a K_i value of 4.5 nM.

HY-B0375R

Argatroban (Standard) MD-805 (Standard); MCI-9038 (Standard)	Reference Standards Thrombin	Cardiovascular Disease Cancer
Argatroban (Standard) is the analytical standard of Argatroban. This product is intended for research and analytical applications. Argatroban (MD-805) is a direct, selective thrombin inhibitor.

HY-105383

L 373890	Thrombin	Cardiovascular Disease
L 373890 is a selective pyridinone acetamide *thrombin* inhibitor with a K_i of 0.5 nM. L 373890 shows highly selectivity for thrombin over trypsin (K_i of 570 nM), serine proteases plasmin, tPA, activated protein C, plasma kallikrein and chymotrypsin. L 373890 can be used for thrombosis research .

HY-12605

SAR107375	Thrombin	Metabolic Disease
SAR107375 is a potent and orally active dual thrombin and factor Xa inhibitor, with K_i values of 1 nM and 8 nM for factor Xa and thrombin, respectively .

HY-142661

BAY 1217224	Thrombin	Neurological Disease
BAY 1217224 is a neutral, non-proagent *Thrombin* inhibitor with good oral pharmacokinetics.

HY-77521

Dabigatran ethyl ester hydrochloride 1 Publications Verification	Thrombin	Cardiovascular Disease
Dabigatran ethyl ester hydrochloride is a potent inhibitor of ribosyldihydronicotinamide dehydrogenase (NQO2) with an IC₅₀ value of 0.8 μM and a *thrombin* inhibitor.

HY-19660

Inogatran H-314-27	Thrombin	Cardiovascular Disease
Inogatran (H-314-27) is a synthetic *thrombin* inhibitor, developed for the possible treatment and prophylaxis of arterial and venous thrombotic diseases.

HY-120452

AZD-8165	Thrombin	Cardiovascular Disease
AZD-8165 is a highly selective neutral thrombin inhibitor. AZD-8165 is promising for research of cardiovascular diseases such as hypertension and heart failure .

HY-15759A

Napsagatran hydrate Ro 46-6240 hydrate; Ro 46-6240/010 hydrate	Thrombin	Cardiovascular Disease
Napsagatran (Ro 46-6240) hydrate is a potent *thrombin* inhibitor. Napsagatran hydrate exhibits anticoagulant effects in vitro and in vivo. Napsagatran hydrate can be used in antithrombotic research ^[1][2].

HY-165436

Toborinone	Phosphodiesterase (PDE)	Cardiovascular Disease
Toborinone is an inotropic agent. Toborinone increases cAMP and intracellular calcium levels through inhibiting PDE. Toborinone inhibits thrombin-induced platelet aggregation with an IC₅₀ of 9.7 μM .

HY-19373

RWJ-445167 3DP-10017	Thrombin Factor Xa	Cardiovascular Disease
RWJ-445167 (3DP-10017) is a dual inhibitor of *thrombin* and factor Xa with K_i of 4.0 nM and 230 nM, respectively, exhibiting potent antithrombotic activity.

HY-162109

Thrombin inhibitor 11	Thrombin	Cardiovascular Disease
Thrombin inhibitor 11 (Compound 46) is an orally active, competitive and selective *α-Thrombin* inhibitor, with a K_i value of 65 nM against h-αThrombin and a K_i value of 10.3 nM against rat-derived α-thrombin. Thrombin inhibitor 11 can be used for the research of thrombotic diseases .

HY-170485

Thrombin inhibitor 13	Thrombin	Cardiovascular Disease
Thrombin inhibitor 13 (Compound 13a) is a covalent and reversible inhibitor for *thrombin* (FIIa) with an IC₅₀ of 0.7 nM. Thrombin inhibitor 13 prolongs the activated partial thromboplastin time (aPTT) and prothrombin time (PT), exhibits antithrombotic and anticoagulant activities .

HY-U00370

Thrombin inhibitor 1	Thrombin	Cardiovascular Disease
Thrombin inhibitor 1 is a potent *thrombin* inhibitor (K_i=0.66 nM, 2xaPTT=0.43 μM).

HY-105392

LB30057 CI-1028; PD 172524	Thrombin	Cardiovascular Disease
LB30057 (CI-1028) is an orally active selective *thrombin* inhibitor with an IC₅₀ value of 0.38 nM for human thrombin. LB30057 can be used in the study of the thrombus model .

HY-106691

Pirmagrel CGS-13080	Thrombin	Endocrinology
Pirmagrel is a thrombin synthetase inhibitor. Pirmagrel has inhibitory effects on thrombin secretion stimulated by lipopolysaccharide (HY-D1056) .

HY-123120

SA-152	Thrombin	Others
SA-152 is an organophosphorus inhibitor. SA-152 modulates the fibrinogen coagulation and TAME esterase activity of bovine α-thrombin .

HY-14878

(2R)-Atecegatran (2R)-AZD-0837	Thrombin	Cardiovascular Disease
(2R)-Atecegatran ((2R)-AZD-0837; (Ph(3-Cl)(5-OCHF2)-(R)CH(OH)C(O)-Aze-Pab)) is a *thrombin* inhibitor. (2R)-Atecegatran can be used in research related to thromboembolic disorders .

HY-19222

CVS-1123	Thrombin	Cardiovascular Disease
CVS-1123 is an orally active direct thrombin inhibitor. CVS-1123 inhibits in vitro platelet aggregation of γ-thrombin and prolongs activated partial thromboplastin time. CVS-1123 alters the thrombotic response to deep vessel wall damage in arterial and venous circulation. CVS-1123 can be used in antithrombotic studies

HY-177804

Thrombin aptamer sodium	Thrombin	Inflammation/Immunology
Thrombin aptamer is a 11mer-DNA aptamer that targets thrombin. Thrombin aptamer inhibites thrombin-catalysed fibrin-clot formation in vitro

HY-19674

SSR182289 SSR182289A free base	Thrombin	Cardiovascular Disease
SSR182289 (SSR182289A free base) is a selective and potent orally active *thrombin* inhibitor. SSR182289 competitively and selectivity inhibits human thrombin (K_i=0.031 μM). SSR182289 demonstrates anticoagulant activity in vitro (thrombin time EC₁₀₀=96 nM) and inhibits tissue factor-induced thrombin generation (IC₅₀=0.15 μM) in human plasma. SSR182289 inhibits thrombin-induced aggregation of human platelets (IC₅₀=32 nM), but has no effect on aggregation induced by other platelet agonists .

HY-N13950

Bacithrocin A	Thrombin Factor Xa Ser/Thr Protease	Cardiovascular Disease
Bacithrocin A is a *thrombin* inhibitor that inhibits thrombin, factor Xa, trypsin and Papain with IC₅₀s of 48 μM, 13 μM, 0.65 μM, and 0.02 μM, respectively .

HY-N13957

Bacithrocin C	Thrombin Factor Xa Ser/Thr Protease	Cardiovascular Disease
Bacithrocin C is a *thrombin* inhibitor that inhibits thrombin, factor Xa, trypsin and Papain with IC₅₀s of 80 μM, 15 μM, 1.3 μM, and 0.02 μM, respectively .

Cat. No.	Product Name

HY-L136

Coagulation and Anti-coagulation Compound Library

1,437 compounds

Coagulation, also known as clotting, is the process in which blood changes from a liquid to a solid gel to form a blood clot. Thrombin, which is accurately and evenly generated in the injured part of blood vessels, is a key effector enzyme of the blood coagulation system and participates in many important biological processes, such as platelet activation, fibrinogen conversion to fibrin network, coagulation feedback amplification, etc. At the same time, to avoid the accidental formation of thrombus in the body, there is also an anticoagulant mechanism that inhibits blood coagulation.

Normal coagulation mechanism represents a balance between the pro-coagulant pathway in the injured site and anti-coagulant pathway beyond it. The blood coagulation system may be out of balance during the perioperative period or critical illness, which may lead to thrombosis or excessive bleeding. Therefore, the physiological study of coagulation balance is an important basis for clinical diagnosis and treatment of the abnormal coagulation process.

MCE supplies a unique collection of 1,437 compounds targeting key proteins in coagulation and anti-coagulation system. MCE Coagulation and Anti-coagulation Compound Library is a useful tool for study the mechanism of coagulation and anticoagulation.

Cat. No.	Product Name	Type

HY-NP019

Agkistrodon halys batroxobin	Biochemical Assay Reagents
Agkistrodon halys batroxobin is a thrombin-like serine protease. Agkistrodon halys batroxobin reduces the expression of Sirt1 and extracellular signal-regulated kinase activation in brain tissue. Agkistrodon halys batroxobin reduces cleaved caspase-3 expression and inhibits neuronal apoptosis in rat .

HY-W087937

Benzamidine hydrochloride hydrate

3 Publications Verification

Benzenecarboximidamide hydrochloride hydrate

Biochemical Assay Reagents

Benzamidine (Benzenecarboximidamide) hydrochloride hydrate is a competitive protease inhibitor that blocks the hydrolytic cleavage of glucagon by plasmin, trypsin and thrombin. Benzamidine hydrochloride hydrate effectively inhibits the degradation of glucagon by relevant proteases during the collection, storage and analysis of human plasma and blood samples. During in vivo metabolism, Benzamidine hydrochloride hydrate undergoes N-hydroxylation and produces multiple metabolites, exhibiting characteristics of delayed excretion or biphasic elimination. Benzamidine hydrochloride hydrate only induces slight single-strand DNA breaks at high concentrations and shows no significant genotoxic potential overall. Benzamidine hydrochloride hydrate may interfere with the detection of some glucagon antisera, but does not affect key antigen-antibody affinity at specific concentrations. Benzamidine hydrochloride hydrate can be used as a stabilizer in glucagon radioimmunoassays to ensure the accuracy and recovery rate of detection results .

Cat. No.	Product Name	Target	Research Area

HY-P1929

Bivalirudin Maximum Cited Publications 9 Publications Verification	Thrombin Interleukin Related RSV	Infection Cardiovascular Disease Inflammation/Immunology
Bivalirudin, a hirudin analog and anticoagulant, is a direct *thrombin* inhibitor. Bivalirudin inhibits thrombin-mediated fibrinogen cleavage, coagulation factor activation, and platelet activation by reversibly binding to thrombin. In addition, Bivalirudin also has certain effects of anti-virus, anti-inflammation, and vascular endothelial barrier function protection. Bivalirudin can be used for the research of thrombotic diseases and others .

HY-P2813

Hirudin 3 Publications Verification	Thrombin Apoptosis	Cardiovascular Disease Cancer
Hirudin is a *thrombin* inhibitor with blood anticoagulant property. Hirudin has potent anti-thrombotic, wound repair, anti-fibrosis, anti-tumor and anti-hyperuricemia effects. Hirudin also affects diabetic complications, cerebral hemorrhage, and others .

HY-P0074

GPRP 3 Publications Verification Gly-Pro-Arg-Pro; Pefa 6003	Thrombin	Cardiovascular Disease
GPRP (Gly-Pro-Arg-Pro; Pefa 6003) is a fibrin polymerization inhibitor that inhibits the interaction between fibrinogen and the platelet membrane glycoprotein Ⅱb/IIIa complex (glycoprotein IIb/IIIa receptor) . GPRP increases the level of free thrombin in activated platelet-rich plasma by reducing the adsorption of *thrombin* onto fibrin. GPRP inhibits platelet aggregation and prolongs the thrombin-initiated clotting time in plasma. GPRP is applicable for research related to thrombosis and thrombotic diseases .

HY-15664

Bivalirudin TFA Maximum Cited Publications 9 Publications Verification	Thrombin Interleukin Related RSV	Infection Cardiovascular Disease Inflammation/Immunology
Bivalirudin TFA, a hirudin analog and anticoagulant, is a direct *thrombin* inhibitor. Bivalirudin TFA inhibits thrombin-mediated fibrinogen cleavage, coagulation factor activation, and platelet activation by reversibly binding to thrombin. In addition, Bivalirudin TFA also has certain effects of anti-virus, anti-inflammation, and vascular endothelial barrier function protection. Bivalirudin TFA can be used for the research of thrombotic diseases and others .

HY-122542

PPACK	PAI-1 Thrombin	Inflammation/Immunology
PPACK is a potent, peptidic inhibitor targeting *thrombin* and granzyme GZMK. PPACK specifically blocks the activities of thrombin and GZMK, thereby inhibiting thrombin-mediated PAR-1 cleavage, as well as downstream inflammatory and procoagulant signaling pathways. Through stabilizing IκB proteins, blocking NF-κB activation and reducing systemic levels of proinflammatory/procoagulant biomarkers, PPACK exerts multiple effects including anti-inflammatory, antithrombotic, barrier repair, and inhibition of atherosclerotic plaque progression. PPACK binds to platelets without interference from kininogen, effectively limiting acute thrombus growth and reducing eosinophil infiltration and goblet cell hyperplasia in asthma models. PPACK is an important tool molecule for investigating the mechanisms of atherosclerosis, asthma and related thromboinflammatory diseases .

HY-P1488

Bradykinin (1-5)	Drug Metabolite	Cardiovascular Disease
Bradykinin (1-5) is a major stable metabolite of Bradykinin (HY-P0206), formed by the proteolytic action of angiotensin-converting enzyme (ACE) . Bradykinin (1-5) inhibits α- and γ-thrombin-induced platelet aggregation .

HY-P1263A

tcY-NH2 TFA 1 Publications Verification (trans-Cinnamoyl)-YPGKF-NH2 TFA	Protease Activated Receptor (PAR)	Metabolic Disease Inflammation/Immunology
tcY-NH2 ((trans-Cinnamoyl)-YPGKF-NH2) TFA is a potent selective PAR4 antagonist peptide. tcY-NH2 TFA inhibits thrombin- and AY-NH₂-induced platelet aggregation and endostatin release, and can be used in the research of inflammation, immunology .

HY-P1263

tcY-NH2 1 Publications Verification (trans-Cinnamoyl)-YPGKF-NH2	Protease Activated Receptor (PAR)	Metabolic Disease Inflammation/Immunology
tcY-NH2 ((trans-Cinnamoyl)-YPGKF-NH2) is a potent selective PAR4 antagonist peptide. tcY-NH2 inhibits thrombin- and AY-NH₂-induced platelet aggregation and endostatin release, and can be used in the research of inflammation, immunology .

HY-P4325

Hirudin (55-65) sulfated	Thrombin	Others
Hirudin (55-65) (sulfated) is a fragment of Hirudin with anticoagulant effects. Hirudin is a thrombin inhibitor with blood anticoagulant property.

HY-P5875A

P4pal10 TFA	Protease Activated Receptor (PAR)	Cardiovascular Disease Inflammation/Immunology
P4pal10 TFA is the TFA salt form of P4pal10 (HY-P5875). P4pal10 TFA is an antagonist for protease-activated receptor 4 (PAR4). P4pal10 TFA inhibits the platelet aggregation, inhibits tissue factor (TF)-induced thrombin generation, and exhibits anticoagulant and antithrombotic activities. P4pal10 TFA reduces the oedema and the granulocyte infiltration induced by Carrageenan (HY-125474). P4pal10 TFA ameliorates the injury in rats myocardial ischemia/reperfusion (I/R) models .

HY-P11260

MD5	Ser/Thr Protease Thrombin	Metabolic Disease
MD5 is a selective TMPRSS6 mimetic peptide inhibitor with an IC₅₀ for recombinant human TMPRSS6 protein of 22 nM and a K_i of 3.4 nM. MD5 exhibits the significantly reduced inhibitory effect on Matriptase, with an IC₅₀ of 352 nM and a K_i of 99.2 nM. MD5 exhibits good target specificity and only has a weak inhibitory effect on thrombin (Thrombin), with K_i of 120 nM. MD5 demonstrates good initial drugability and can be used for the study of iron overload diseases (such as hereditary hemochromatosis, β-thalassemia) .

HY-W109513

Boc-Lys(Z)-OH (DCHA)	Amino Acid Derivatives	Inflammation/Immunology
Boc-Lys(Z)-OH (DCHA) is a involves in synthesis thymosin β4, βg and β6 fragments, and increases E-rosette forming capacity in Lupus Nephritis model. Boc-Lys(Z)-OH (DCHA) involves in synthesis Boc-Lyz-OCH3 and acts as a reagent of peptidyl thrombin inhibitors production .

HY-P2021

BMS 180742	Thrombin	Cardiovascular Disease
BMS 180742 is a *thrombin* exosite inhibitor. BMS 180742 does not inhibit arterial thrombosis .

HY-P4259

Hirullin P18	Thrombin	Cardiovascular Disease
Hirullin P18 is a potent *thrombin* inhibitor. Hirullin P18 has an anticoagulant effect .

HY-P1636A

Hirudin (54-65) TFA	Thrombin	Cardiovascular Disease
Hirudin (54-65) TFA is a fragment of Hirudin with anticoagulant effects. Hirudin is a thrombin inhibitor with blood anticoagulant property .

HY-P4795

Acetyl-Hirudin (55-65) sulfated	Thrombin	Others
Acetyl-Hirudin (55-65) (sulfated) is a Acetyl-fragment of Hirudin. Hirudin is a thrombin inhibitor with blood anticoagulant property .

HY-P1261

Parstatin(mouse)	Protease Activated Receptor (PAR)	Cardiovascular Disease Inflammation/Immunology
Parstatin(mouse), a cell-penetrating *PAR-1 thrombin* receptor** agonist peptide, is a potent inhibitor of angiogenesis .

HY-P1262

Parstatin(human)	Protease Activated Receptor (PAR)	Cardiovascular Disease Inflammation/Immunology
Parstatin(human), a cell-penetrating *PAR-1 thrombin* receptor** agonist peptide, is a potent inhibitor of angiogenesis .

HY-P1261A

Parstatin(mouse) TFA	Protease Activated Receptor (PAR)	Cardiovascular Disease Inflammation/Immunology
Parstatin(mouse) TFA, a cell-penetrating *PAR-1 thrombin* receptor** agonist peptide, is a potent inhibitor of angiogenesis .

HY-P1262A

Parstatin(human) TFA	Protease Activated Receptor (PAR)	Cardiovascular Disease Inflammation/Immunology
Parstatin(human) TFA, a cell-penetrating *PAR-1 thrombin* receptor** agonist peptide, is a potent inhibitor of angiogenesis .

HY-P4721

Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) sulfated	Thrombin	Cardiovascular Disease
Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) is a hirugen-like peptide, and has high affnity for thrombin than Hirugen, with a K_D < 100 nM. Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) is an antithrombotic agent. Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) inhibits the thrombin-induced fibrin clot formation with an IC50 value of 0.087 μM .

HY-P4302

Z-FK-ck Z-Phe-Lys-2,4,6-Trimethylbenzoyloxy-methylketone	Cathepsin	Cardiovascular Disease
Z-FK-ck (Z-Phe-Lys-2,4,6-Trimethylbenzoyloxy-methylketone) is a potent and selective gingipain-K-specific inhibitor. Z-FK-ck prolongs plasma thrombin time (TT) in a dose- and time-dependent manner .

HY-P5875

P4pal10	Protease Activated Receptor (PAR)	Cardiovascular Disease Inflammation/Immunology
P4pal10 is an antagonist for protease-activated receptor 4 (PAR4). P4pal10 inhibits the platelet aggregation, inhibits tissue factor (TF)-induced thrombin generation, and exhibits anticoagulant and antithrombotic activities. P4pal10 reduces the oedema and the granulocyte infiltration induced by Carrageenan (HY-125474). P4pal10 ameliorates the injury in mice myocardial ischemia/reperfusion (I/R) models .

HY-P2102

BCH-2763	Thrombin	Cardiovascular Disease
BCH-2763 is a potent and selective *Thrombin* inhibitor. BCH-2763 has a very high affinity for thrombin (K_i = 0.11 nM). BCH-2763 can effectively inhibit fibrin formation, platelet aggregation, and free thrombin activity. BCH-2763 can be used for the study of thrombosis .

HY-P4269

Glycylglycylcysteine	Peptides	Cardiovascular Disease
Glycylglycylcysteine is a Thrombin Activatable Fibrinolysis Inhibitor (TAFI) inhibitor with a K_i of 0.99 μM and a IC₅₀ of 9.4 μM in TAFI substrate assays. TAFI is a basic carboxypeptidase that functions as a fibrinolysis inhibitor through the cleavage of C-terminal lysine on partially degraded fibrin .

HY-P1488A

Bradykinin (1-5) TFA	Drug Metabolite	Cardiovascular Disease
Bradykinin (1-5) (TFA) is a major stable metabolite of Bradykinin (HY-P0206), formed by the proteolytic action of angiotensin-converting enzyme (ACE). Bradykinin (1-5) (TFA) inhibits α- and γ-thrombin-induced platelet aggregation .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99794

Osocimab BAY 1213790	Factor Xa	Cardiovascular Disease
Osocimab (BAY 1213790), an anti-FXIa antibody (K_i=2.4 nM; EC₅₀=0.2 nM). FXI inhibition may reduce the risk of thrombosis. Osocimab inhibits thrombin generation, and prolongs activated partial thromboplastin time. Osocimab exhibits anticoagulant effects .

HY-108739

Idarucizumab BI 655075	Thrombin	Cardiovascular Disease
Idarucizumab is a humanized monoclonal antibody fragment. Idarucizumab is first reversal agent for a direct oral anticoagulant (DOAC). Idarucizumab can specifically neutralize the effects of the oral direct thrombin inhibitor in order to restore hemostasis .

HY-P991065

Ichorcumab JNJ-375; JNJ-64179375; JNJ-9375	Thrombin	Cardiovascular Disease
Ichorcumab (JNJ-375) is a fully human IgG4 antibody that targets *Thrombin. Ichorcumab binds to exosite 1 on thrombin* and inhibits substrate binding but not catalytic activity. The isotype control for Ichorcumab can refer to Human IgG4 kappa, Isotype Control (HY-P99003) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-P2813

Hirudin 3 Publications Verification	Cardiovascular Disease Natural Products Animals Classification of Application Fields Disease Research Fields Source Classification Cancer	Thrombin Apoptosis
Hirudin is a *thrombin* inhibitor with blood anticoagulant property. Hirudin has potent anti-thrombotic, wound repair, anti-fibrosis, anti-tumor and anti-hyperuricemia effects. Hirudin also affects diabetic complications, cerebral hemorrhage, and others .

HY-N3097

Pellitorine	Alkaloids Classification of Application Fields Other Alkaloids Piperaceae Plants Disease Research Fields Piper nigrum Linn. Biological Pesticide Research Source Classification Cancer Agricultural Research	TRP Channel Amyloid-β Toll-like Receptor (TLR) Keap1-Nrf2 Heme Oxygenase (HO) Dihydroorotate Dehydrogenase Ferroptosis PAI-1 NF-κB ERK Proton Pump Glutathione Peroxidase Thrombin Insecticide Bacterial
Pellitorine is a bioactive natural amide compound. Pellitorine can competitively antagonize the activation of TRPV1 by Capsaicin (HY-10448), thereby reducing pain signal transmission. Pellitorine improves cognitive dysfunction by upregulating the BDNF-ERK1/2-CREB and Nrf2-HO-1 pathways. Pellitorine exerts anti-inflammatory and anti-sepsis effects by inhibiting the release of high mobility group protein B1 (HMGB1) and the expression of RAGE/TLR4. Pellitorine exerts its antithrombotic effect by prolonging the clotting time, inhibiting the activity of clotting factors and thrombin. Pellitorine inhibits lipid peroxidation and resists ferroptosis by upregulating GPX4 and DHODH. Pellitorine kills Aedes aegypti mosquito larvae by inhibiting V-type H⁺-ATPase and aquaporin 4 (AaAQP4). Pellitorine exhibits anti-cancer activity (e.g., leukemia and breast cancer) and has inhibitory effects on certain bacteria .

HY-N1400

(20R)-Ginsenoside Rh1	Panax ginseng C. A. Meyer Triterpenes Structural Classification Classification of Application Fields Terpenoids Plants Disease Research Fields Araliaceae Source Classification Cancer	PKC
(20R)-Ginsenoside Rh1 is the R-isomer of Ginsenoside Rh1 (HY-N0604), and it is found in red ginseng, ginseng, and other sources. (20R)-Ginsenoside Rh1 inhibits thrombin-induced conversion of fibrinogen to fibrin, exerting anticoagulant and antithrombotic effects .

HY-N1745A

3-Deoxysappanchalcone 2 Publications Verification	Structural Classification Chalcones Flavonoids Classification of Application Fields Leguminosae Caesalpinia sappan L. Phenols Polyphenols Plants Inflammation/Immunology Disease Research Fields Source Classification	Influenza Virus
3-Deoxysappanchalcone is a kinase inhibitor and antiviral agent. 3-Deoxysappanchalcone directly targets MET, EGFR, AKT, mTOR, p38 MAPK, JNK, thrombin, FXa, and influenza virus neuraminidase, thereby regulating related signaling pathways. 3-Deoxysappanchalcone induces cell cycle arrest, ROS production, and apoptosis. 3-Deoxysappanchalcone exhibits anti-inflammatory, anti-allergic, anticoagulant, and antithrombotic activities. 3-Deoxysappanchalcone is applicable to research related to gefitinib-resistant lung cancer, esophageal squamous cell carcinoma, thrombosis, and influenza virus infection .

HY-N2082

Isorhamnetin 3-O-galactoside 1 Publications Verification Cacticin	Cardiovascular Disease Flavonols Flavonoids Typhaceae Classification of Application Fields Typha angustifolia L. Phenols Polyphenols Plants Disease Research Fields Source Classification	Thrombin COX ERK JNK Factor Xa
Isorhamnetin 3-O-galactoside (Cacticin) is a flavonoid glycoside that can be isolated from Oenanthe javanica, with antithrombotic and profibrinolytic activities. Isorhamnetin 3-O-galactoside inhibits the activities of *thrombin* and factor Xa (FXa) and reduces thrombin-catalyzed fibrin polymerization maximum rate. Isorhamnetin 3-O-galactoside suppresses TNF-α-induced PAI-1 secretion, decreases the PAI-1/tissue-type plasminogen activator (t-PA) ratio, and inhibits FXa production and FVa/FXa-mediated *thrombin* generation. Isorhamnetin 3-O-galactoside exerts protective effects against Carbon tetrachloride (CCl4) (HY-Y0298)-induced hepatic injury in mice. Isorhamnetin 3-O-galactoside can be used for the study of liver injury-related diseases and thrombotic vascular diseases .

HY-N10762

15,16-Dihydrotanshindiol C	Terpenoids Labiatae Samanea saman (Jacq.) Merr. Diterpenoids Plants Source Classification	Thrombin
15,16-Dihydrotanshindiol C, a diterpenoid, is a potent *thrombin* inhibitor .

HY-N13950

Bacithrocin A	Natural Products Microorganisms Source Classification	Thrombin Factor Xa Ser/Thr Protease
Bacithrocin A is a *thrombin* inhibitor that inhibits thrombin, factor Xa, trypsin and Papain with IC₅₀s of 48 μM, 13 μM, 0.65 μM, and 0.02 μM, respectively .

HY-N13957

Bacithrocin C	Natural Products Microorganisms Source Classification	Thrombin Factor Xa Ser/Thr Protease
Bacithrocin C is a *thrombin* inhibitor that inhibits thrombin, factor Xa, trypsin and Papain with IC₅₀s of 80 μM, 15 μM, 1.3 μM, and 0.02 μM, respectively .

HY-N13955

Bacithrocin B	Natural Products Microorganisms Source Classification	Thrombin Factor Xa Ser/Thr Protease
Bacithrocin B is a *thrombin* inhibitor that inhibits thrombin, factor Xa, trypsin and Papain with IC₅₀s of 84 μM, 17 μM, 1.7 μM, and 0.02 μM, respectively .

HY-N15271

Oxopurpureine	Alkaloids Plants Annonaceae Annona purpurea Moc. & Sessé ex Dunal Isoquinoline Alkaloids Source Classification	Thrombin Platelet-activating Factor Receptor (PAFR)
Oxopurpureine is an oxoaporphine with antiplatelet aggregation activity. Oxopurpureine inhibits collagen, thrombin and arachidonic acid-induced platelet aggregation and can be utilized in relevant research .

HY-N10271

SCH 38519	Infection Quinones Monophenols Microorganisms Classification of Application Fields Anthraquinones Phenols Disease Research Fields Source Classification	Bacterial
SCH 38519 is a platelet aggregation inhibitor. SCH 38519 inhibits thrombin-induced aggregation of human platelets with an IC₅₀ of 68 μg/mL. SCH 38519 is also active against Gram-positive and Gram-negative bacteria .

HY-N13960

Bacithrocin D Thiolstatin D	Natural Products Microorganisms Ketones, Aldehydes, Acids Source Classification	Thrombin Factor Xa
Bacithrocin D (Thiolstatin D) inhibits multiple proteases and can prolong the clotting time. Bacithrocin D has IC₅₀ values of 124, 9, 0.85, and 0.01 μM for thrombin, factor Xa, trypsin, and papain, respectively .

HY-N13897

Avidinorubicin	Quinones Microorganisms Anthraquinones Source Classification	Antibiotic Bacterial
Avidinorubicin is an antibiotic found in Streptomyces avidinii, exhibiting activity against both Gram-positive and Gram-negative bacteria. Additionally, Avidinorubicin inhibits thrombin (HY-114164)-induced platelet aggregation, with an IC₅₀ of 7.9 μM .

HY-167686

Variabilin Homopisatin	Structural Classification Natural Products Plants Dalbergia variabilis Fabaceae Source Classification	Integrin
Variabilin (Homopisatin) is a potent RGD-containing antagonist of glycoprotein IIb-IIIa and platelet aggregation inhibitor from the hard tick Dermacentor variabilis. Variabilin potently inhibits platelet aggregation induced by the platelet agonists ADP, collagen, and thrombin receptor peptide SFLLRNP. Variabilin also blocks platelet adhesion to immobilized Fg. In addition, Variabilin inhibits binding of purified human GPIIb-IIIa to immobilized Fg .

HY-N16369

1,2-Di-(9Z-hexadecenoyl)-sn-glycerol	Microorganisms Antibiotics Other Antibiotics Source Classification	Thrombin
1,2-Di-(9Z-hexadecenoyl)-sn-glycerol (Compound 2e) is a diacylglycerol derivative that can be isolated from the fungus Stereum Hirsutum. 1,2-Di-(9Z-hexadecenoyl)-sn-glycerol has potential *thrombin*-inhibiting activity and can be used in research related to antithrombotic drugs .

HY-N1400R

(20R)-Ginsenoside Rh1 (Standard)	Panax ginseng C. A. Meyer Triterpenes Structural Classification Terpenoids Plants Araliaceae Source Classification	Reference Standards PKC
(20R)-Ginsenoside Rh1 (Standard) is the analytical standard of (20R)-Ginsenoside Rh1 (HY-N1400). This product is intended for research and analytical applications. (20R)-Ginsenoside Rh1 is the R-isomer of Ginsenoside Rh1 (HY-N0604), and it is found in red ginseng, ginseng, and other sources. (20R)-Ginsenoside Rh1 inhibits thrombin-induced conversion of fibrinogen to fibrin, exerting anticoagulant and antithrombotic effects .

HY-N3097R

Pellitorine (Standard)	Alkaloids Other Alkaloids Piperaceae Plants Piper nigrum Linn. Source Classification	Reference Standards TRP Channel Amyloid-β Toll-like Receptor (TLR) Keap1-Nrf2 Heme Oxygenase (HO) Dihydroorotate Dehydrogenase Ferroptosis PAI-1 NF-κB Proton Pump Glutathione Peroxidase Thrombin Insecticide Bacterial
Pellitorine (Standard) is the analytical standard of Pellitorine (HY-N3097). Pellitorine is a bioactive natural amide compound. Pellitorine can competitively antagonize the activation of TRPV1 by Capsaicin (HY-10448), thereby reducing pain signal transmission. Pellitorine improves cognitive dysfunction by upregulating the BDNF-ERK1/2-CREB and Nrf2-HO-1 pathways. Pellitorine exerts anti-inflammatory and anti-sepsis effects by inhibiting the release of high mobility group protein B1 (HMGB1) and the expression of RAGE/TLR4. Pellitorine exerts its antithrombotic effect by prolonging the clotting time, inhibiting the activity of clotting factors and thrombin. Pellitorine inhibits lipid peroxidation and resists ferroptosis by upregulating GPX4 and DHODH. Pellitorine kills Aedes aegypti mosquito larvae by inhibiting V-type H⁺-ATPase and aquaporin 4 (AaAQP4). Pellitorine exhibits anti-cancer activity (e.g., leukemia and breast cancer) and has inhibitory effects on certain bacteria.

Species:	Human (3)
Tag:	His (3) Trx (1)
Source:	HEK293 (1) Sf9 insect cells (1) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P70970

	Serpin B6 Protein, Human (Trx-His) Serpin B6; Cytoplasmic Antiproteinase; CAP; Peptidase inhibitor 6; PI-6; Placental thrombin inhibitor; SERPINB6; PI6; PTI	Human	E. coli
	Serpin B6 protein acts as a potential modulator of serine proteases in the brain or blood. It inhibits cathepsin G, kallikrein 8, and thrombin, suggesting a role in protease regulation. Serpin B6 Protein, Human (Trx-His) is the recombinant human-derived Serpin B6 protein, expressed by E. coli , with N-Trx, N-6*His labeled tag.

HY-P76640

	Serpin B6 Protein, Human (sf9, His) Serpin B6; Cytoplasmic Antiproteinase; CAP; Peptidase inhibitor 6; PI-6; Placental thrombin inhibitor; SERPINB6; PI6; PTI	Human	Sf9 insect cells
	Serpin B6 protein acts as a potential modulator of serine proteases in the brain or blood. It inhibits cathepsin G, kallikrein 8, and thrombin, suggesting a role in protease regulation. Serpin B6 Protein, Human (sf9, His) is the recombinant human-derived Serpin B6 protein, expressed by Sf9 insect cells , with N-His labeled tag.

HY-P7735

	Carboxypeptidase B2/CPB2 Protein, Human (HEK293, His) rHuCarboxypeptidase B2, His; Carboxypeptidase B2; Carboxypeptidase U; Plasma Carboxypeptidase B; thrombin-Activable Fibrinolysis inhibitor; CPB2	Human	HEK293
	Carboxypeptidase B2 Protein, Human (HEK293, His) is an approximately 47.0 kDa human carboxypeptidase B2 with a His-flag. Carboxypeptidase B2 is a enzyme belonging to the peptidase M14 family and hydrolyze C-terminal peptide bonds.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-10163S

Dabigatran-d4
Dabigatran-d₄ is deuterium labeled Dabigatran. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC₅₀=10 nM) .

HY-10264S

Edoxaban-d6

Edoxaban-d₆ is deuterium labeled Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention. Edoxaban is also a weak inhibitor of thrombin and factor IXaβ (FIXa), with Kis of 6.00 μM and 41.7 μM, respectively, exhibits >10000-fold selectivity for FXa. Edoxaban has antithrombotic properties and has potential for thromboembolic diseases treatment .

HY-10163S1

Dabigatran-d3
Dabigatran-d₃ is the deuterium labeled Dabigatran. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC₅₀=10 nM) .

HY-10163AS

Dabigatran-d4 hydrochloride
Dabigatran-d₄ (hydrochloride) is deuterium labeled Dabigatran, which is a reversible and selective, direct thrombin inhibitor (DTI) with a K_i value of 4.5 nM.

HY-12605S

SAR107375-d11 Tartrate
SAR107375-d₁₁ (Tartrate) is deuterium labeled SAR107375. SAR107375 is a potent and orally active dual thrombin and factor Xa inhibitor, with K_i values of 1 nM and 8 nM for factor Xa and thrombin, respectively .

HY-10163S2

Dabigatran-13C6
Dabigatran- ¹³C₆ is the ¹³C labeled Dabigatran . Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC₅₀=10 nM) .

HY-10163S3

Dabigatran-13C,d3
Dabigatran- ¹³C,d₃ is the ¹³C- and deuterium labeled Dabigatran. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC₅₀=10 nM) .

HY-B0375S

Argatroban-d3
Argatroban-d₃ is the deuterium labeled Argatroban. Argatroban (MD-805) is a direct, selective thrombin inhibitor.

HY-10163S5

Dabigatran-d7
Dabigatran-d₇ (BIBR 953-d₇; BIBR 953ZW-d₇) is the deuterium labeled Dabigatran (HY-10163). Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC₅₀=10 nM) .

HY-B0375S1

Argatroban-13C6 hydrochloride
Argatroban- ¹³C₆ hydrochloride is ¹³C labeled Argatroban (HY-B0375). Argatroban (MD-805) is a direct, selective thrombin inhibitor.

HY-10119S

Vorapaxar-d5
Vorapaxar-d₅ is deuterated labeled Vorapaxar (HY-10119). Vorapaxar (SCH 530348), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor protease-activated receptor (PAR-1) antagonist (K_i=8.1 nM). Vorapaxar (SCH 530348) inhibits thrombin receptor-activating peptide (TRAP)-induced platelet aggregation in a dose-dependent manner .

HY-W743984

Melagatran-d11

Melagatran-d₁₁ is the deuterium labeled Melagatran (HY-129056). Melagatran is a direct and orally active inhibitor of thrombin, without interacting with any other enzymes in the coagulation cascade or fibrinolytic enzymes aside from thrombin. Melagatran does not require endogenous co-factors for its antithrombin effect and may help to alleviate some of the damaging effects of endotoxemia . Melagatran has the potential to provide a rational approach in the prevention of arterial occlusion .

HY-W705434

Dabigatran etexilate-d11
Dabigatran etexilate-d₁₁ (BIBR 1048-d₁₁) is the deuterium labeled Dabigatran etexilate (HY-10274). Dabigatran etexilate (BIBR 1048) is an orally active proagent of Dabigatran (a direct inhibitor of thrombin). Dabigatran etexilate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation .

HY-18660S

Ciraparantag-d8 (tetra(hydrochloride) diacetate)

Ciraparantag-d₈ (PER977-d₈) tetrahydrochloride diacetate is the deuterium labeled Ciraparantag (HY-18660). Ciraparantag is a thrombin and factor Xa inhibitor. Ciraparantag is a broad-spectrum reversal agent for anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants. It is reported to antagonize the effects of all coagulants except VKAs and agratroban .

Cat. No.	Product Name		Classification

HY-132587

Fitusiran ALN-AT3SC; SAR439774		siRNAs siRNA drugs
Fitusiran (ALN-AT3SC) is a siRNA strategy. Fitusiran delivers siRNA targeting the SERPINC1 gene in hepatocytes to inhibit antithrombin synthesis. Fitusiran enhances thrombin activity and increases *Thrombin* generation, thereby restoring hemostatic function. Fitusiran can be used in hemophilia-related research .

HY-132587A

Fitusiran sodium ALN-AT3SC sodium; SAR439774 sodium		siRNAs siRNA drugs
Fitusiran (ALN-AT3SC) sodium is a siRNA strategy. Fitusiran delivers siRNA targeting the SERPINC1 gene in hepatocytes to inhibit antithrombin synthesis. Fitusiran sodium enhances thrombin activity and increases *Thrombin* generation, thereby restoring hemostatic function. Fitusiran sodium can be used in hemophilia-related research .

HY-153480A

ARC19499 sodium 1 Publications Verification BAX499 sodium		Aptamers
ARC19499 sodium is an aptamer that inhibits tissue factor pathway inhibitor (TFPI) , thereby enabling clot initiation and propagation via the extrinsic pathway. The core aptamer binds tightly and specifically to TFPI. ARC19499 sodium blocks TFPI inhibition of both factor Xa and the TF/factor VIIa complex. ARC19499 sodium corrects thrombin generation in hemophilia A and B plasma and restores clotting in FVIII-neutralized whole blood.

HY-153480

ARC19499 BAX499		Aptamers
ARC19499 is an aptamer that inhibits tissue factor pathway inhibitor (TFPI) , thereby enabling clot initiation and propagation via the extrinsic pathway. The core aptamer binds tightly and specifically to TFPI. ARC19499 blocks TFPI inhibition of both factor Xa and the TF/factor VIIa complex. ARC19499 corrects thrombin generation in hemophilia A and B plasma and restores clotting in FVIII-neutralized whole blood.

HY-177804

Thrombin aptamer sodium		Aptamers
Thrombin aptamer is a 11mer-DNA aptamer that targets thrombin. Thrombin aptamer inhibites thrombin-catalysed fibrin-clot formation in vitro

HY-132587C

Fitusiran sodium scrambled negative control		siRNAs siRNA drugs
Fitusiran sodium scrambled negative control is the sequence scrambled negative control of Fitusiran sodium. Fitusiran (ALN-AT3SC) sodium is a siRNA strategy. Fitusiran delivers siRNA targeting the SERPINC1 gene in hepatocytes to inhibit antithrombin synthesis. Fitusiran sodium enhances thrombin activity and increases *Thrombin* generation, thereby restoring hemostatic function. Fitusiran sodium can be used in hemophilia-related research .

HY-132587E

Cy3 labled Fitusiran sodium		siRNAs siRNA drugs
Cy3 labled Fitusiran sodium is a Cy3 labled Fitusiran sodium (HY-132587A). Fitusiran (ALN-AT3SC) sodium is a siRNA strategy. Fitusiran delivers siRNA targeting the SERPINC1 gene in hepatocytes to inhibit antithrombin synthesis. Fitusiran sodium enhances thrombin activity and increases *Thrombin* generation, thereby restoring hemostatic function. Fitusiran sodium can be used in hemophilia-related research .

HY-132587D

FAM labled Fitusiran sodium		siRNAs siRNA drugs
FAM labled Fitusiran sodiumis a FAM labled Fitusiran sodium (HY-132587A). Fitusiran (ALN-AT3SC) sodium is a siRNA strategy. Fitusiran delivers siRNA targeting the SERPINC1 gene in hepatocytes to inhibit antithrombin synthesis. Fitusiran sodium enhances thrombin activity and increases *Thrombin* generation, thereby restoring hemostatic function. Fitusiran sodium can be used in hemophilia-related research .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

thrombin inhibitor

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products